Evidence map›Paper›PMID 40214978›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025

Causal Effects of Breast Cancer Risk Factors across Hormone Receptor Breast Cancer Subtypes: A Two-Sample Mendelian Randomization Study.

Renée M G Verdiesen, Mehrnoosh Shokouhi, Stephen Burgess, Sander Canisius, Jenny Chang-Claude, Stig E Bojesen, Marjanka K Schmidt

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Renée M G Verdiesen *Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.ORCID 0000-0002-2061-0530
Mehrnoosh Shokouhi *Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.ORCID 0009-0004-8165-4571
Stephen BurgessThe Medical Research Council (MRC) Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-5365-8760
Sander CanisiusDivision of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.ORCID 0000-0003-3888-8829
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-8919-1971
Stig E BojesenCopenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.ORCID 0000-0002-4061-4133
Marjanka K SchmidtDivision of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.ORCID 0000-0002-2228-429X

Funding

Epidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6M
Epidemiological and Clinical Translational Studies Post Genome-Wide AssociationU19CA148537 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EASTON, DOUGLAS FREDERICK, EELES, ROSALIND · 2010 to 2014
$10.4M
Ovarian cancer GWAS discovery, expansion and replication (N2 - Project #1)U19CA148112 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2010 to 2014
$10.2M
A genome-wide association study for breast cancer in BRCA1 mutation carriersR01CA128978 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH · 2008 to 2012
$4.8M
Antonie van Leeuwenhoek FoundationBreast Cancer Research Foundation (BCRF)Canadian Institutes of Health Research (CIHR) CRN-87521Cancer Research UK 10118Cancer Research UK 10692Cancer Research UK 10710Cancer Research UK 11174Cancer Research UK 12014Cancer Research UK 15007Cancer Research UK 16563Cancer Research UK 16565Cancer Research UK 20861Cancer Research UK (CRUK) C12292/A11174Cancer Research UK (CRUK) C12292/A20861Cancer Research UK (CRUK) C1281/A12014Cancer Research UK (CRUK) C1287/A10118Cancer Research UK (CRUK) C1287/A10710Cancer Research UK (CRUK) C1287/A16563Cancer Research UK (CRUK) C5047/A10692Cancer Research UK (CRUK) C5047/A15007Cancer Research UK (CRUK) C5047/A8384Cancer Research UK (CRUK) C8197/A16565Cancer Research UK (CRUK) PPRPGM-Nov20\100002Fondation du cancer du sein du Québec (FCSQ)Genome Canada (GC) GPH-129344Gray FoundationHorizon 2020 Framework Programme (H2020) 633784Horizon 2020 Framework Programme (H2020) 634935KWF Kankerbestrijding (DCS)Medical Research Council (MRC) MC_UU_00002/7Medical Research Council (MRC) MC_UU_00040/01Ministère de l'Économie, de la Science et de l'Innovation - Québec (MESI) PSRSIIRI-701National Institutes of Health (NIH) CA128978National Institutes of Health (NIH) CA148065National Institutes of Health (NIH) CA148112National Institutes of Health (NIH) X01HG007492NCI NIH HHS R01 CA128978NCI NIH HHS U19 CA148065NCI NIH HHS U19 CA148112NCI NIH HHS U19 CA148537Ovarian Cancer Research Fund (OCRF)Seventh Framework Programme (FP7) 223175 (HEALTH-F2-2009-223175)Susan G. Komen (SGK)The Dutch Ministry of Health, Welfare and SportU.S. Department of Defense (DOD) W81XWH-10-1-0341Wellcome Trust 100114Wellcome Trust (WT) 225790/Z/22/Z
6 · The paper itself

Abstract

backgroundIt is unclear if established breast cancer risk factors exert similar causal effects across hormone receptor breast cancer subtypes. We estimated and compared causal estimates of height, body mass index (BMI), type 2 diabetes, age at menarche, age at menopause, breast density, alcohol consumption, regular smoking, and physical activity across these subtypes.

methodsWe used a two-sample Mendelian randomization approach and selected genetic instrumental variables from large-scale genome-wide association studies. Publicly available summary-level Breast Cancer Association Consortium data (n = 247,173; 133,384 cases, 113,789 controls) for the following subtypes were included: luminal A-like (45,253 cases), luminal B-/HER2-negative-like (6,350 cases), luminal B-like (6,427 cases), HER2-enriched (2,884 cases), and triple-negative (8,602 cases). We employed multiple Mendelian randomization methods to evaluate the strength of causal evidence for each risk factor-subtype association.

resultsCollectively, our analyses indicated that increased height and decreased BMI are probable causal risk factors for all five subtypes. For the other risk factors, the strength of evidence for causal effects differed across subtypes. Heterogeneity in the magnitude of causal effect estimates for age at menopause and breast density was explained by null findings for triple-negative tumors. Regular smoking was the sole risk factor for which there was no evidence of a causal effect on any subtype.

conclusionsThis study suggests that established breast cancer risk factors differ across hormone receptor subtypes. IMPACT: Our results are valuable for the development of primary prevention strategies, improvement of breast cancer risk stratification in the general population, and identification of novel breast cancer risk factors.

Indexed as

Breast NeoplasmsBody Mass IndexErb-b2 Receptor Tyrosine KinasesFemaleGenome-Wide Association StudyHumansMendelian Randomization AnalysisMiddle AgedReceptors, EstrogenReceptors, ProgesteroneRisk FactorsErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID40214978
PMCPMC12130805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.